SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Sheli L. Ostrow, Einav Simon, Elad Prinz, Tova Bick, Talia Shentzer, Sima S. Nagawkar, Edmond Sabo, Ofer Ben-Izhak, Ruth Hershberg, Dov Hershkovitz, Variation in KRAS driver substitution distributions between tumor types is determined by both mutation and natural selection, Scientific Reports, 2016, 6, 21927

    CrossRef

  2. 2
    Michael J Duffy, Personalized treatment for patients with colorectal cancer: role of biomarkers, Biomarkers in Medicine, 2015, 9, 4, 337

    CrossRef

  3. 3
    Marco Miroddi, Carmelo Sterrantino, Ilaria Simonelli, Giorgio Ciminata, Robert S. Phillips, Gioacchino Calapai, Risk of grade 3-4 diarrhea and mucositis in colorectal cancer patients receiving anti-EGFR monoclonal antibodies regimens: A meta-analysis of 18 randomized controlled clinical trials, Critical Reviews in Oncology/Hematology, 2015, 96, 2, 355

    CrossRef

  4. 4
    Tze-Kiong Er, Chih-Chieh Chen, Luis Bujanda, Marta Herreros-Villanueva, Clinical relevance of KRAS mutations in codon 13: Where are we?, Cancer Letters, 2014, 343, 1, 1

    CrossRef

  5. 5
    Miguel Jhonatan Sotelo Lezama, Javier Sastre Valera, Eduardo Díaz-Rubio García, Impact of cetuximab in current treatment of metastatic colorectal cancer, Expert Opinion on Biological Therapy, 2014, 14, 3, 387

    CrossRef

  6. You have free access to this content6
    C A Federico, B Carlisle, J Kimmelman, D A Fergusson, Late, never or non-existent: the inaccessibility of preclinical evidence for new drugs, British Journal of Pharmacology, 2014, 171, 18
  7. 7
    Donatella Marino, Francesco Leone, Francesca D’Avanzo, Dario Ribero, Lorenzo Capussotti, Massimo Aglietta, Potentially resectable metastatic colorectal cancer: An individualized approach to conversion therapy, Critical Reviews in Oncology/Hematology, 2014, 92, 3, 218

    CrossRef

  8. 8
    Douglas J. Hartman, Simion I. Chiosea, Colorectal carcinomas, KRAS p.G13D mutant allele–specific imbalance, and anti–epidermal growth factor receptor therapy, Cancer, 2013, 119, 24